# Public co-investment in first-in-class phase 1 with a royalty return

Source: https://onco.cc/ideas/idea-fund-sovereign-first-in-class-coinvestment/  
OnCo record `idea-fund-sovereign-first-in-class-coinvestment` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A public investment fund would match private money in the riskiest early trials of truly new cancer drugs, taking a small share of future royalties so that taxpayers gain when the bets pay off.

## Summary

A sovereign or supranational fund co-invests one-to-one alongside private investors in phase 1 trials of assets that meet a first-in-class test (a target or mechanism with no approved analogue), in exchange for a royalty stake or equity. The fund's return is portfolio-level and long-term; its purpose is to lower the private cost of capital for novel mechanisms relative to me-too assets. The Cancer Prevention and Research Institute of Texas (CPRIT) and the California Institute for Regenerative Medicine (CIRM) show public bodies can invest in translational biotech with revenue-sharing and attract companies; the EU's Innovative Health Initiative and BARDA venture arms are related models.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Public co-investment reduces the first-in-class discount in private financing (the gap in valuation and time to raise between novel and follow-on assets) measurably within five years and yields a portfolio return that covers the fund's costs within fifteen.
- Rationale: CPRIT has committed billions with a documented multiplier in private follow-on investment and company relocation; CIRM funded therapies now in late-stage trials. Public capital is patient and can accept the higher failure rate of novelty in exchange for a share of rare large wins.
- Proposed test: Capitalise a fund at $500 million, invest only in assets passing an independent first-in-class test, and compare private follow-on financing and time-to-phase-2 of funded assets against matched unfunded novel assets after five years.
- Maturity: speculative
- Actor: policy

## Sources

- CPRIT: https://www.cprit.texas.gov/
- CIRM: https://www.cirm.ca.gov/

## Connected records

- ideas: [A diversified royalty pool that finances academic phase 1 trials across fifty assets](https://onco.cc/ideas/idea-fund-royalty-pool-academic-assets/), [A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks](https://onco.cc/ideas/idea-fund-ind-enabling-fund/), [Government reinsurance for phase 2 failures of first-in-class cancer drugs](https://onco.cc/ideas/idea-fund-phase-two-failure-reinsurance/)
- institutions: [Cancer Prevention and Research Institute of Texas](https://onco.cc/institutions/cprit/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-sovereign-first-in-class-coinvestment.json